Greenwich LifeSciences, Inc. announced progress in its Phase III clinical trial FLAMINGO-01, which is studying its immunotherapy GLSI-100 to prevent breast cancer recurrences. The European ...

Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

Telethon Foundation is seeking approval for a gene therapy to treat the rare disease Wiskott-Aldrich syndrome.

This is unusual, as dropout rates typically range from 15-30%, with many trials aiming to ... or a small sample size. This could have biased results in favor of the active treatment, blarcamesine.

Cyclo Therapeutics’ Trappsol Cyclo was able to induce clinical improvement in seven out of eight children with Neimann-Pick ...

Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...

What this means is that using the CHMP date as an endpoint results in an artificial deflation of EMA ... example, the FDA consistently (15 out of 15 times) approved a drug before its European ...

The recommendations are part of the ACT EU initiative between the European Commission, the European Medicines Agency (EMA), and ... study found, for example, that 43% of trials deployed at least ...

Pharmaceutical Market Size and Growth 2025 to 2034The global pharmaceutical market size was valued at USD 1,607.07 billion in ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closureInterim analysis planned ...

Analysis of the open label data from FLAMINGO-01 has commenced and has been conducted in a manner that maintains the study blind. A preliminary review of FLAMINGO-01 HLA data in both the HLA-A*02 ...